Health care stocks advanced late Monday afternoon, with the NYSE Health Care Index up 0.2% and the Health Care Select Sector SPDR Fund (XLV) adding 0.1%.
The iShares Biotechnology ETF (IBB) climbed 1.6%.
In corporate news, Genmab (GMAB) shares rose nearly 4% after it said Monday new cohort data from its phase 1/2 trial of rinatabart sesutecan to treat patients with advanced endometrial cancer showcased "encouraging" anti-tumor activity and a 47.1% confirmed objective response rate at a dosage of 120 milligrams per square meter, every three weeks.
Sanofi (SNY) agreed to buy biopharmaceutical company Blueprint Medicines (BPMC) in a deal worth up to $9.5 billion, as the French drugmaker seeks to expand its immunology portfolio. Sanofi shares shed 0.4% and Blueprint jumped 26%.
Bristol Myers Squibb (BMY) and BioNTech (BNTX) said Monday they have agreed to co-develop and co-commercialize an investigational bispecific therapy across various solid tumor types. Bristol Myers shares added 1.1% and BioNTech jumped 18%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.